ScholarLens Back to search
2019•Cochrane Database of Systematic ReviewsOpen access

Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children

Miri Golos, Noa Eliakim‐Raz, Anat Stern, Leonard Leibovici, Mical Paul

Open full text 19 citations

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to compare the effects of pneumococcal conjugated vaccines (PCV) alone or added to a pneumococcal polysaccharide vaccine (PPSV) versus PPSV alone for the prevention of any pneumonia. Secondary objectives are: 1. to compare the effect of PCV versus PPSV vaccine on any IPD and IPD caused by VT serotypes; 2. to compare the effect of PCV versus PPSV vaccine on VT pneumonia and any pneumonia requiring hospitalisation; 3. to examine the effects of PCV versus PPSV on immunological outcomes (antibodies level; opsonophagocytic activity); 4. to compare the effect of PCV versus PPSV on serotype replacement; and 5. to compare the adverse events caused by PCV to the adverse events caused by PPSV.

About this research paper

What this paper is about

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to compare the effects of pneumococcal conjugated vaccines (PCV) alone or added to a pneumococcal polysaccharide vaccine (PPSV) versus PPSV alone for the prevention of any pneumonia. Secondary objectives are: 1. to compare the effect of PCV versus PPSV vaccine on any IPD and IPD caused by VT serotypes; 2. to compare the effect of PCV versus PPSV vaccine on VT pneumonia and any pneumonia requiring hospitalisation; 3. to examine the effects of PCV versus PPSV on immunological outcomes (antibodies level; opsonophagocytic activity); 4. to compare the effect of PCV versus PPSV on serotype replacement; and 5. to compare the adverse events caused by PCV to the adverse events caused by PPSV.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to compare the effects of pneumococcal conjugated vaccines (PCV) alone or added to a pneumococcal polysaccharide vaccine (PPSV) versus PPSV alone for the prevention of any pneumonia. Secondary objectives are: 1. to compare the effect of PCV versus PPSV vaccine on any IPD and IPD caused by VT serotypes; 2. to compare the effect of PCV versus PPSV vaccine on VT pneumonia and any pneumonia requiring hospitalisation; 3. to examine the effects of PCV versus PPSV on immunological outcomes (antibodies level; opsonophagocytic activity); 4. to compare the effect of PCV versus PPSV on serotype replacement; and 5. to compare the adverse events caused by PCV to the adverse events caused by PPSV.

Key concepts: Pneumococcal disease, Pneumococcal vaccine, Medicine, Pneumonia, Pneumococcal pneumonia, Immunology, Timeline, Disease

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children — Research Paper | ScholarLens